## Liz Lightstone

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4599346/publications.pdf

Version: 2024-02-01

76326 71685 6,353 117 40 76 citations h-index g-index papers 124 124 124 8268 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Annals of the Rheumatic Diseases, 2012, 71, 1771-1782.	0.9	868
2	Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Annals of the Rheumatic Diseases, 2013, 72, 1280-1286.	0.9	382
3	Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet, The, 2021, 397, 1178-1181.	13.7	279
4	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology, 2018, 57, e1-e45.	1.9	247
5	Genetic loci influencing kidney function and chronic kidney disease. Nature Genetics, 2010, 42, 373-375.	21.4	246
6	Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. Annals of the Rheumatic Diseases, 2021, 80, 1322-1329.	0.9	188
7	Goodpasture's disease. Lancet, The, 2001, 358, 917-920.	13.7	155
8	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Annals of the Rheumatic Diseases, 2017, 76, 543-546.	0.9	154
9	Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. American Journal of Kidney Diseases, 2002, 39, 1162-1167.	1.9	143
10	Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrology Dialysis Transplantation, 2009, 24, 3717-3723.	0.7	141
11	European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus, 2009, 18, 257-263.	1.6	131
12	High Prevalence of Asymptomatic COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. Journal of the American Society of Nephrology: JASN, 2020, 31, 1969-1975.	6.1	128
13	Diagnostic and predictive biomarkers for pre-eclampsia in patients with established hypertension and chronic kidney disease. Kidney International, 2016, 89, 874-885.	5.2	124
14	Clinical practice guideline on pregnancy and renal disease. BMC Nephrology, 2019, 20, 401.	1.8	124
15	Breastfeeding and Tacrolimus. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 563-567.	4.5	114
16	Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney International, 2003, 64, 1685-1694.	5.2	102
17	Lupus nephritis management guidelines compared. Nephrology Dialysis Transplantation, 2016, 31, 904-913.	0.7	97
18	Pregnancy in chronic kidney disease and kidney transplantation. Kidney International, 2017, 91, 1047-1056.	5.2	96

#	Article	IF	Citations
19	Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology, 2006, 45, 1497-1504.	1.9	90
20	The Endogenous Pathway of MHC Class II Antigen Presentation. Immunological Reviews, 1996, 151, 51-79.	6.0	85
21	In Goodpasture's Disease, CD4+ T Cells Escape Thymic Deletion and Are Reactive with the Autoantigen $\hat{1}\pm3$ (IV)NC1. Journal of the American Society of Nephrology: JASN, 2001, 12, 1908-1915.	6.1	72
22	Quinine-induced immune thrombocytopenic purpura followed by hemolytic uremic syndrome. American Journal of Kidney Diseases, 1999, 33, 133-137.	1.9	70
23	Serum Creatinine in Pregnancy: A Systematic Review. Kidney International Reports, 2019, 4, 408-419.	0.8	70
24	Severe pre-eclampsia and hypertensive crises. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2013, 27, 877-884.	2.8	69
25	Tacrolimus is an effective treatment for lupus nephritis in pregnancy. Lupus, 2014, 23, 1192-1196.	1.6	68
26	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	4.5	66
27	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus. Annals of Internal Medicine, 2021, 174, 1647-1657.	3.9	64
28	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmunity Reviews, 2009, 9, 82-89.	5.8	62
29	Natural regulatory T cells: number and function are normal in the majority of patients with lupus nephritis. Clinical and Experimental Immunology, 2008, 153, 44-55.	2.6	60
30	Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology, 2018, 57, 1156-1161.	1.9	58
31	Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. Kidney International, 2021, 99, 1470-1477.	5.2	58
32	Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients. Lancet, The, 2021, 398, 1482-1484.	13.7	58
33	Type I interferons affect the metabolic fitness of CD8+ T cells from patients with systemic lupus erythematosus. Nature Communications, 2021, 12, 1980.	12.8	56
34	Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study. American Journal of Kidney Diseases, 2020, 76, 679-689.	1.9	56
35	Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic featuresÂonÂrenal biopsy. Kidney International, 2017, 92, 1223-1231.	5.2	55
36	High Rates of Tuberculosis in End-Stage Renal Failure: the Impact of International Migration. Emerging Infectious Diseases, 2002, 8, 77-78.	4.3	51

#	Article	IF	CITATIONS
37	Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 937-948.	4.5	47
38	In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 5772-5777.	7.1	46
39	Pre-pregnancy counseling for women with chronic kidney disease. Journal of Nephrology, 2012, 25, 450-459.	2.0	44
40	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology, 2018, 57, 14-18.	1.9	43
41	The impact of chronic kidney disease Stages 3–5 on pregnancy outcomes. Nephrology Dialysis Transplantation, 2021, 36, 2008-2017.	0.7	43
42	Eculizumab as rescue therapy in severe resistant lupus nephritis: Fig. 1. Rheumatology, 2015, 54, kev307.	1.9	40
43	Lupus Nephritis and Pregnancy: Concerns and Management. Seminars in Nephrology, 2017, 37, 347-353.	1.6	39
44	Randomized, Controlled Trial of Tacrolimus and Prednisolone Monotherapy for Adults with De Novo Minimal Change Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 209-218.	4.5	38
45	Rituximab in Systemic Lupus Erythematosus and Lupus Nephritis. Nephron Clinical Practice, 2015, 128, 250-254.	2.3	37
46	Can we manage lupus nephritis without chronic corticosteroids administration?. Autoimmunity Reviews, 2018, 17, 4-10.	5.8	37
47	Lupus nephritis: where are we now?. Current Opinion in Rheumatology, 2010, 22, 252-256.	4.3	34
48	The landscape after LUNAR: Rituximab's craterâ€filled path. Arthritis and Rheumatism, 2012, 64, 962-965.	6.7	34
49	Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. Nephrology Dialysis Transplantation, 2017, 32, i123-i128.	0.7	33
50	Glomerular membrane attack complex is not a reliable marker of ongoing C5 activation in lupus nephritis. Kidney International, 2019, 95, 655-665.	5.2	33
51	Results from the IRoc-GN international registry of patients with COVID-19 and glomerular disease suggest close monitoring. Kidney International, 2021, 99, 227-237.	5.2	33
52	Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?. Nephrology Dialysis Transplantation, 2018, 33, 1604-1610.	0.7	32
53	Updates in Diagnosis and Management of Preeclampsia in Women with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1371-1380.	4.5	32
54	Antigen presentation by T cells inhibits IL-2 production and induces IL-4 release due to altered cognate signals. Journal of Immunology, 1996, 156, 2769-75.	0.8	32

#	Article	IF	Citations
55	Informing the Risk of Kidney Transplantation Versus Remaining onÂtheÂWaitlist in the Coronavirus Disease 2019 Era. Kidney International Reports, 2021, 6, 46-55.	0.8	28
56	Antigen presentation by dendritic cells provides optimal stimulation for the production of interleukin (IL) 2, IL 4 and interferon- $\hat{l}^3$ by allogeneic T cells. European Journal of Immunology, 1991, 21, 2803-2809.	2.9	27
57	Lesson of the week: Cholesterol emboli syndrome. BMJ: British Medical Journal, 2000, 321, 1065-1067.	2.3	27
58	Comparison of Vaccine Effectiveness Against the Omicron (B.1.1.529) Variant in Hemodialysis Patients. Kidney International Reports, 2022, 7, 1406-1409.	0.8	26
59	Minimising steroids in lupus nephritis – will B cell depletion pave the way?. Lupus, 2013, 22, 390-399.	1.6	25
60	Haplotype structure of TNFRSF5-TNFSF5 (CD40–CD40L) and association analysis in systemic lupus erythematosus. European Journal of Human Genetics, 2005, 13, 669-676.	2.8	23
61	Diagnostic Indicators of Superimposed Preeclampsia in Women With CKD. Kidney International Reports, 2019, 4, 842-853.	0.8	23
62	Anti-cd45ra antibodies increase the proliferation of mouse t cells to phytohemagglutinin through the interleukin 2/interleukin 2 receptor pathway. European Journal of Immunology, 1989, 19, 2005-2010.	2.9	22
63	Renoprotective strategies in lupus nephritis: beyond immunosuppression. Lupus, 2013, 22, 1267-1273.	1.6	21
64	Expressionin vivo of CD45RA, CD45RB and CD44 on T cell receptor-transgenic CD8+ T cells following immunization. European Journal of Immunology, 1995, 25, 1755-1759.	2.9	20
65	Standardized Outcomes in Nephrology—Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. Kidney International, 2019, 95, 1280-1283.	5.2	20
66	Memory in helper T cells of minor histocompatibility antigens, revealedin vivo by alloimmunizations in combination with Thy-1 antigen. European Journal of Immunology, 1992, 22, 115-122.	2.9	19
67	A Multicenter Cohort Study of Histologic Findings and Long-Term Outcomes of Kidney Disease in Women Who Have Been Pregnant. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 408-416.	4.5	19
68	Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. Autoimmunity Reviews, 2018, 17, 11-18.	5.8	19
69	The exaggerated inflammatory response in Behçet's syndrome: identification of dysfunctional post-transcriptional regulation of the IFN- $\hat{I}^3$ /CXCL10 IP-10 pathway. Clinical and Experimental Immunology, 2015, 181, 427-433.	2.6	17
70	Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening. Transplantation, 2021, 105, 151-157.	1.0	17
71	High incidence of end-stage renal disease in Indo-Asians in the UK. QJM - Monthly Journal of the Association of Physicians, 1995, , .	0.5	16
72	Pregnancy in pancreas–kidney transplant recipients: report of three cases and review of the literature. Obstetric Medicine, 2010, 3, 73-77.	1.1	16

#	Article	IF	CITATIONS
73	LACK OF AWARENESS OF KIDNEY COMPLICATIONS DESPITE FAMILIARITY WITH DIABETES: A MULTIâ€ETHNIC QUALITATIVE STUDY. Journal of Renal Care, 2011, 37, 2-11.	1.2	16
74	Preventing renal disease: The ethnic challenge in the United Kingdom. Kidney International, 2003, 63, S135-S138.	<b>5.</b> 2	15
75	Kidneys and women's health: key challenges and considerations. Nature Reviews Nephrology, 2018, 14, 203-210.	9.6	15
76	CD45RA+ T Cells: Not Simple Virgins. Clinical Science, 1993, 85, 515-519.	4.3	14
77	Necrotizing and crescentic glomerulonephritis presenting with preserved renal function in patients with underlying multisystem autoimmune disease: a retrospective case series. Rheumatology, 2015, 54, 1025-1032.	1.9	12
78	Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patientsâ€"a potential biomarker of disease activity. Rheumatology, 2017, 56, 1206-1216.	1.9	12
79	Glomerular Disease in Women. Kidney International Reports, 2018, 3, 258-270.	0.8	12
80	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. Rheumatology, 2018, 57, 1502-1503.	1.9	12
81	Placental and endothelial biomarkers for the prediction of superimposed pre-eclampsia in chronic kidney disease. Pregnancy Hypertension, 2021, 24, 58-64.	1.4	12
82	In the mouse the maturation stage of the peripheral CD4+ CD45RA+ subset is different from that of the CD8+ CD45RA+ subset. European Journal of Immunology, 1991, 21, 2161-2165.	2.9	11
83	Hyper-reactivity of mouse CD45RAâ^' T cells. European Journal of Immunology, 1993, 23, 2383-2386.	2.9	11
84	COVID-19 in Patients with Glomerular Disease: Follow-Up Results from the IRoc-GN International Registry. Kidney360, 2022, 3, 293-306.	2.1	10
85	Distal renal tubular acidosis in association with HIV infection and AIDS. Nephrology Dialysis Transplantation, 2006, 21, 1420-1422.	0.7	9
86	Lifeâ€threatening thrombosis 18 years after first presentation of primary antiphospholipid antibody syndrome. Nephrology Dialysis Transplantation, 2001, 16, 843-845.	0.7	8
87	Anti-M $\tilde{\text{A}}$ 1/4llerian hormone concentrations in women with chronic kidney disease. CKJ: Clinical Kidney Journal, 2021, 14, 537-542.	2.9	7
88	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. Kidney International, 2021, 100, 881-893.	5.2	7
89	Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial. BMC Nephrology, 2019, 20, 352.	1.8	6
90	Glomerular Disease and Pregnancy. Advances in Chronic Kidney Disease, 2020, 27, 469-476.	1.4	6

#	Article	IF	CITATIONS
91	Answering the call to action: rapid implementation of an in-center hemodialysis SARS-CoV-2 vaccination program. Kidney International, 2021, 99, 1238-1239.	5.2	6
92	Acute renal failure. Clinical Medicine, 2001, 1, 266-273.	1.9	5
93	A multi-centre qualitative study exploring the experiences of UK South Asian and White Diabetic Patients referred for renal care. BMC Nephrology, 2012, 13, 157.	1.8	5
94	SARS-CoV-2 Antibody Point-of-Care Testing in Dialysis and Kidney Transplant Patients With COVID-19. Kidney Medicine, 2021, 3, 54-59.e1.	2.0	5
95	Kidney disease and pregnancy. Medicine, 2015, 43, 550-555.	0.4	4
96	A Core Outcome Set for Trials in Glomerular Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 53-64.	4.5	4
97	Serologic Screening for Coronavirus Disease 2019 in Patients With Glomerular Disease. Kidney International Reports, 2021, 6, 1402-1406.	0.8	3
98	Immune gene expression and functional networks in distinct lupus nephritis classes. Lupus Science and Medicine, 2022, 9, e000615.	2.7	3
99	END-STAGE RENAL FAILURE IN INDO-ASIANS IN THE UK: A DOUBLE WHAMMY. Transplantation, 2002, 73, 1533-1534.	1.0	2
100	Prepregnancy counselling and risk assessment: general overview., 0,, 21-30.		2
101	Renal disease and pregnancy. Medicine, 2011, 39, 497-501.	0.4	2
102	A complicated multisystem flare of systemic lupus erythematosus during pregnancy. BMJ Case Reports, 2017, 2017, bcr2016217546.	0.5	2
103	MO126CLINICAL AND BIOMARKER CHARACTERISTICS OF PATIENTS WITH C3G OR IC-MPGN ENROLLED IN TWO PHASE II STUDIES INVESTIGATING THE FACTOR D INHIBITOR DANICOPAN*. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	2
104	A focus group study of self-management in patients with glomerular disease Kidney International Reports, 2021, 7, 56-67.	0.8	2
105	Comparison of catheters or new arteriovenous fistulas for commencement of haemodialysis in pregnant women with chronic kidney disease: an international observational study. Journal of Nephrology, 2022, 35, 1689-1698.	2.0	2
106	A patient with suspected miscarriage is found to have hypertension, renal failure, and thrombocytopenia: case outcome. BMJ: British Medical Journal, 2007, 335, 205-206.	2.3	1
107	Renal disease and pregnancy. Medicine, 2007, 35, 524-528.	0.4	1
108	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Diseaseâ€"The Berlin Roadmap. Kidney International Reports, 2016, 1, 327-339.	0.8	1

#	Article	IF	CITATIONS
109	Manifestations of lupus in the kidney and how to manage them. Nephrology Dialysis Transplantation, 2017, 32, 1614-1616.	0.7	1
110	FP187TWENTY YEARS OF LUPUS NEPHRITIS MANAGEMENT - EVALUATION OF A MULTI ETHNIC PATIENT COHORT TO IDENTIFY FACTORS AFFECTING OUTCOME. Nephrology Dialysis Transplantation, 2018, 33, i92-i92.	0.7	1
111	Chapter 16 Systemic Lupus Erythematosus: Renal Involvement. Handbook of Systemic Autoimmune Diseases, 2007, , 311-321.	0.1	O
112	A patient with suspected miscarriage is found to have hypertension, renal failure, and thrombocytopenia: case presentation. BMJ: British Medical Journal, 2007, 334, 1372-1372.	2.3	0
113	A patient with suspected miscarriage is found to have hypertension, renal failure, and thrombocytopenia: case progression. BMJ: British Medical Journal, 2007, 335, 44-44.	2.3	O
114	Postpartum follow-up of antenatally identified renal problems. , 0, , 53-58.		0
115	Seasonal Relapsing Minimal Change Disease: A Novel Strategy for Avoiding Long-Term Immunosuppression. Case Reports in Nephrology and Urology, 2012, 2, 102-107.	1.5	O
116	Lupus and Vasculitis in Pregnancy. , 0, , 157-169.		0
117	BLISS-LN trial revisited: function matters. Kidney International, 2022, 101, 224-226.	5.2	O